Early cancer detection saves lives — but the flip side of sensitive screening is a wave of false positives that can upend patients' lives even when no cancer is found. Dr. Jason Hafron, chief medical officer at the Michigan Institute of Urology, is sounding the alarm on the frequently overlooked emotional, clinical, and financial toll of false positive results across common screening modalities like PSA testing, mammography, low-dose CT lung scans, and thyroid nodule detection.

When patients hear "positive," they assume the worst — and the anxiety, sleep disruption, and fear that follow don't always disappear even after a benign result. Beyond the psychological burden, false positives set off a cascade of additional imaging, biopsies, specialist referrals, and invasive procedures, all of which carry their own risks and costs while straining healthcare resources.

Hafron points to next-generation tools as a path forward, highlighting the IsoPSA test — which analyzes PSA protein structure to better distinguish cancer from benign causes — and Cx Bladder Triage as examples of smarter risk stratification in action.

Key Takeaways:

• A retrospective study of 1,578 patients showed those with low initial IsoPSA indices had a significantly lower risk of clinically significant prostate cancer
• False positives can permanently alter how patients engage with healthcare, making some reluctant to pursue future screening
• Clear, upfront communication about the possibility of false positives is critical to maintaining patient trust

Why it matters: The future of cancer screening isn't just earlier detection — it's smarter detection. Tools that reduce unnecessary interventions protect patients from harm while preserving the life-saving benefits of catching cancer early.